- A “smart” move: The development of electronic devices for nasal aerosols
- A clinically relevant approach to assess in vitro bioequivalence for regulatory approval of DPIs: A case study
- A forensic approach to particulate contamination in inhalable drug products
- A history of DPI capsule filling
- A novel aerodynamic sizing method for pharmaceutical aerosols using image-based analysis of settling velocities
- A practical method for eliminating type I and type II errors when assessing the suitability for continued use of a cascade impactor
- Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts: A partnership for the assurance of Oral Inhaled Product (OIP) quality
- Accelerating inhalation product development: Choosing between outsourcing and developing internal capabilities
- Accuracy in the optical inspection of impactor nozzles—More to it than meets the eye
- Addressing the patient-device use interface: Development and laboratory validation of a facemask with anatomically-responsive face models
- Addressing the patient-device use interface: Why patient-friendly features are important
- Advantages of capsule-based dry powder inhalers
- Aerosolized adhesive coating of cascade impactor plates
- An approach to particle size stability
- An Introduction to IPAC-RS
- An overview of general chapter development for oral and nasal drug products (OINDPs) at the US Pharmacopeia (USP): Part 1—Normative chapters <5>, <601>, <602>, <603> and <604>
- An overview of general chapter development for oral and nasal drug products (OINDPs) at the US Pharmacopeia (USP): Part 2—Informative chapters <1601>, <1602>, <1603> and <1604>
- An update on solid-state physicochemical characterization and microscopy of particles in dry powder inhalers
- Analytical instrumentation for solid state characterization of inhalable formulations
- Application of organotypic in vitro human cell culture models for research and development of inhalation pharmaceutical formulations targeting the proximal airways
- Applications of automated scanning electron microscopy—energy dispersive spectroscopy (SEM-EDS) for inhalable drug products
- Applying QbD principles to device selection
- Assessing the role of breathing simulators in OIP testing
- Atomic force microscopy (AFM): A quantitative tool for excipient screening of pMDI formulations
- Automated Inhaler Testing
- Avoiding pitfalls obtaining inhalation patents at the European Patent Office
- Back Page: A free online tutorial about cascade impaction from the IPAC-RS CI working group
- Back Page: A more accurate tool to predict asthma in young children
- Back Page: Acoustic emission for characterization of inhaler performance
- Back Page: Amish farming methods and significantly reduced asthma in children
- Back Page: Black children in US six times more likely to die of asthma
- Back Page: Bridges for the asthma achievement gap
- Back Page: Comic books help educate kids about asthma and proper inhaler use
- Back Page: Controlled release formulations for inhalation: Soon to appear?
- Back Page: Exercise induced bronchoconstriction: The role of inhaled therapy in identifying stimulus and mechanism
- Back Page: Exploring the potential of mannitol as an alternative to lactose in dry powder inhalation
- Back Page: First comprehensive lung cell map leads to new findings and implications for asthma
- Back Page: Free San Antonio, Texas program supports children with asthma and their families
- Back Page: High maternal sugar intake during pregnancy associated with allergy and allergic asthma in children
- Back Page: Humble giant of cascade impactors, Virgil A. Marple; August 16, 1939 to December 24, 2017
- Back Page: Increasing participation in and improving outcomes from pMDI training
- Back Page: Inhalatorium: A website dedicated to the history of inhalation therapy
- Back Page: Inhaled medical aerosols: A new training course in the Hawaiian Islands
- Back Page: Inhaler digital sensors help correlate reductions in power plant emissions and improvements in asthma
- Back Page: Is asthma a risk factor for COVID-19? Answers are evolving and likely to be complex
- Back Page: Lessons from UK asthma deaths: Improving asthma care
- Back Page: Leveraging digital health technology: Five ways to address barriers to inhaled medication adherence
- Back Page: Mimicking cigarette smoke exposure and patient-specific responses
- Back Page: Modeling paradigms for orally inhaled drugs
- Back Page: New system enables more donor lungs to be transplanted
- Back Page: NIH issues new guidelines for prevention of peanut allergy in children
- Back Page: On the design of comparator clinical studies
- Back Page: Past Inhalation covers, with thanks to our three charter advertisers!
- Back Page: Poplar trees genetically modified not to damage air quality grow as well as non-modified trees
- Back Page: Reasons for e-cigarette use among US middle and high school students: The National Youth Tobacco Survey 2016
- Back Page: Reducing carbon footprints of metered dose inhalers
- Back Page: Researchers quantitatively link traffic pollution to four million annual cases of childhood asthma
- Back Page: Rules in pharmacy and music: More in common than you might believe!
- Back Page: School-based telemedicine combined with in-school care helped children manage asthma
- Back Page: The EFA’s Active Asthma and COPD Patients ACCESS Care Report
- Back Page: The pediatric asthma yardstick
- Back Page: The Teal Pumpkin Project helps children with food allergies celebrate Halloween safely
- Back Page: Type of grass pollen, not total pollen count, may be useful for people with allergies
- Back Page: US FDA approves OTC, non-CFC-based Primatene® Mist; Patient advocacy groups object
- Back Page: Use of antibiotics in infants correlates with allergies in children, though causation not shown
- Back Page: Why do we know so little about absorption pathways in the lung?
- Calibrating cascade impactors with particles—Approaches and pitfalls
- Cascade impactor flow control
- Cascade impactor stage groupings: Poor decisions from degraded data
- Cascade Impactors
- Characterizing carrier-free DPI formulations
- Chemical-selective imaging of adhesive mixtures for inhalation using coherent anti-Stokes Raman scattering (CARS) microscopy
- Choosing a micronizer for inhalation powders
- Choosing between capsules and blisters
- Combined impactor and x-ray diffraction (XRPD) methodology for characterizing polymorph impurities in inhalation powders
- Comparison between in vitro performance of the Child “Alberta” Idealized Throat and Ph.Eur./USP induction port for the delivery of salbutamol sulfate inhalation aerosol by pressurized metered dose inhaler
- Connected inhalers: Stakeholders’ potential benefits and possible concerns
- Considerations in selecting a contract manufacturing organization
- Considerations in spray dry drug development for inhalation delivery: An albuterol case study
- Contributions of mechanical stress on the “frustrated” thermal response of griseofulvin
- Critical evaluation of the revised and new USP chapters for aerosols: and [Pharm Forum 2011; 37(4)]
- CROs and OINDP development
- Defining the dosage strength for labeling of DPIs: Use, limitations and relevance of in vitro data
- Delivering orally inhaled medications to the older patient with COPD and/or asthma: A challenge in both device design and clinical approach
- Delivery of inhaled bronchodilators by breath-actuated jet nebulizer: The potential for improved adherence with clinical guidelines
- Design of an inhaler-specific robotic system for laboratory use in early development
- Designing a DPI for multiple constituencies
- Developing OINDPs using Quality by Design
- Development of HFA-152a as an environmentally sustainable propellant for pressurized metered dose inhalers
- Development of inhalable dry-powder formulations for low water-soluble products using spray-dried engineered particles
- Dissolution testing for inhalation formulations
- DPI development: Understanding the technical challenges
- Dry powder inhalers—More than 170 years of development; Where to next?
- E-cigarettes: Learnings for inhalation scientists
- Effect of conditioning on rat lung function measurements and implications for exposure and dose estimation of inhaled drugs
- Effective inhalation treatment for acute fungal infections
- Elastomers in orally inhaled and nasal drug products, Part I: Elastomer selection and qualification
- Elastomers in orally inhaled and nasal drug products, Part II: Control strategies
- Engineering combination particles
- Enhancing drug product portfolios for nasal aerosols and buccal spray delivery systems
- Evaluating simulated patient use in realistic nasal airway models for the in vitro characterization of nasal spray products
- Evaluating the Alberta Throat: An innovation to support the acquisition of more clinically applicable aerosol aerodynamic particle size distribution (APSD) data in oral inhaled product (OIP) development
- Evaluating the performance of orally inhaled products in the laboratory: Why clinically appropriate testing is important
- Evolution of nasal aerosol products for pain management
- Examining the influence of carrier lactose on the performance of dry powder inhaler (DPI) formulations: A case study
- Excipients in DPI Formulations
- Formulation and characterization of nasal sprays
- Formulation concepts for small-volume nebulizers: Challenges and opportunities
- From actuation to deposition: Particle sizing techniques for characterizing nasal drug delivery systems
- Functional respiratory imaging (FRI): An alternative to pulmonary function tests (PFTs)
- Functional respiratory imaging (FRI): Enhancing biomarker sensitivity to expedite drug development
- Gaining new insights into pressurized metered dose inhaler (pMDI) design using synchrotron radiation
- Gaps in statistical approaches to control of delivered dose uniformity throughout product lifecycle
- Gene–environment interactions in asthma: Lessons for the development of new drugs for asthma
- Getting started with CFD
- Good practices for Abbreviated Impaction Measurements (AIM) in dry powder inhalers (DPIs)
- HFA Propellants
- High pressure homogenization as an alternative methodology to micronization for obtaining effective inhalation particles
- How to participate in respiratory drug delivery meetings
- Human factors and inhalation pharmaceuticals: Manifestations, mitigations and regulatory issues
- Human factors studies in the development of a new nasal delivery device
- Image analysis for particle characterization
- Imaging techniques for dry powder inhaler capsules
- Impact of capsule selection on formulation stability in dry powder inhalers (DPIs)
- Implementing the AIM concept
- Improving dose reproducibility from MDIs
- In vitro bioequivalence testing of nasal sprays
- In vitro nasal spray characterization
- In vitro particle deposition in the nasal cavity
- Ingredient-specific particle sizing
- Inhalation to the small airways
- Inhalation toxicity of graphene and its derivatives
- Inhaled administration of drugs to animals in pharmaceutical research
- Inhaled drug product development: A unique form of product life cycle management
- Inhaled therapies for tuberculosis: A viable approach for spray-dried drugs delivered by handheld dry powder inhaler
- Innovation in analytical tools: More signal and less noise in particle size testing of inhaled products
- Inspecting used impactors—Practice and principles
- Interaction of nanomaterials at the air-liquid interface of the lung
- Intranasal vaccination
- Intranasal Vaccines: Protecting Public Safety
- Inverse gas chromatography
- LC-MSD as a platform for inhalation product development
- MDI propellants
- Measuring particle adhesive ability
- Measuring powder properties
- Measuring the cold freon effect
- Meeting expectations for FDA nasal spray Q3 structural equivalence
- Microcrystallization for inhalation particles
- Micromolding as a potential manufacturing route for dry powder formulations
- Nasal and sublingual spray delivery devices: Market opportunities and unmet medical needs
- Nasal and trans-nasal lung deposition of aerosols
- Nasal drug delivery devices: Past, present and future device innovations for the would-be product developer
- Nasal spray regulatory approval
- Nebulizer testing
- Nebulizers: Past to present platforms and future possibilities (2016)
- Nebulizers: Past to present platforms and future possibilities (2018)
- New cascade impactor software
- Obscuring the message: A critical examination of laboratory test methods for orally inhaled products that could lead the user astray: Part 1—Aerodynamic Particle Size Distribution (APSD)
- Obscuring the message: A critical examination of laboratory test methods for orally inhaled products that could lead the user astray: Part 2—Total Emitted Mass (TEM) and related metrics
- OINDP device regulation
- Opportunities for capsule-based DPIs in emerging markets
- Optimizing the role of automation in variability reduction strategies for delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD) testing of inhaled drug products
- Outsourcing inhalation product development
- Overcoming challenges in development of nasal vaccines through intelligent particle engineering
- Overlooked opportunities for nebulizers in inhalation product development
- Parameters to consider in software for respiratory drug and device testing
- Particle design for respiratory drug delivery: Challenges and processing options
- Particle engineering approaches for dry powder inhalers
- Particle engineering by practical and scalable, intensive, mechanical, dry coating processes to develop highly efficient dry powder inhaler formulations
- Particle engineering for inhalation formulation and delivery of biotherapeutics
- Pharmacoscintigraphy
- PK bioequivalence testing when between-batch variability is high: A multiple-batch proposal
- Point of View: Overcoming barriers to affordability of orally inhaled products while protecting innovation
- Point of View: Recommendations to a young scientist to pursue inhalation research
- Principles of nebulizer technology
- Product development: Case study of an inhaled biologic
- Progress in particle engineering science: Towards advanced dry powder inhalation systems
- Q&A: Mechanical surface modification
- Quality by design: Considerations for inhalation product development
- Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part I: A grassroots look
- Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part II: The concept of “sufficient” as applied to impactor quality specifications
- Redundancy Based Development (RBD) for a dry powder inhaler
- Regulatory considerations for cybersecurity and data privacy in digital health and medical applications and products
- Respirable, engineered, spray-dried dry powders for 505(b)(2) drug product development
- Risk management for combination products
- Selecting a dose counter
- Selecting a nasal spray pump
- Selecting an MDI can
- Significant advances in laboratory testing of orally inhaled products during the ten-year life of Inhalation
- Significant restriction of the delivered dose uniformity criteria in the revised USP Chapter for Aerosols
- Simplifying OINDP regulations
- Solid-state physicochemical characterization and microscopy of particles in dry powder inhalers (2016)
- Solid-state physicochemical characterization and microscopy of particles in dry powder inhalers (2019)
- Spray pattern as a screening tool during early development of nasal sprays
- Spray pattern: A rapid and sensitive early development tool for respiratory drug products
- Spray-granulated mannitol as a viable alternative to lactose in DPI formulations: Preparation of ordered mixtures and storage stability
- Surface science and particle interactions in dry powders for inhalation
- Technology selection in capsule-based inhalation product development
- Terahertz characterization of lactose
- Testing and comparison of puncturing forces for gelatin and HPMC inhalation capsules
- Testing the equivalence of aerodynamic particle size distributions
- The Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) concepts: Why they are important and how to work with them
- The abbreviated impactor measurement concept
- The Asthma Insight and Management survey
- The effect of shaking on solution MDIs
- The electrical Next Generation Impactor
- The evolution of DPI capsules
- The Good Cascade Impactor Practice (GCIP) Concept: A systematic approach to risk management of erroneous measurements in the assessment of inhaler emitted aerosol aerodynamic particle size distributions (APSDs)
- The impact of intratracheal aerosol technologies on preclinical pulmonary research
- The importance of human factors in inhaler development: The making of PowdAir®
- The influence of lactose fines in dry powder inhaler formulations
- The liability of fine particle dose (FPD)
- The Lovelace Respiratory Research Institute
- The lung as a dissolution vessel?
- The Next Generation Impactor (NGI™)—Manufacturing Control: Part I. Nozzles
- The Next Generation Impactor (NGI™)—Manufacturing Control: Part II. Collection Cups and the Critical Jet-to-Plate Distance
- The pressurized metered dose inhaler: Past, present and future perspectives
- The regulatory landscape for OINDPs—the biggest shake-up in a generation?
- The role of intelligent sorbents in respiratory drug delivery devices
- The role of the Hydraulic Lung in comparing the performance of dry powder inhalers
- The use of cyclodextrins in formulations for lung delivery
- Thixotropic sprays: Popular with patients, challenging for developers
- Trends in nasal delivery
- Unit-dose aseptic packaging of nasal drugs
- Unveiling dislocations in API crystallinity after mechanical stress due to milling
- US Payers and OINDPS
- Using MDIs to deliver pDNA
- Web-based inhalation training
- What is the future of HFA pMDIs? A patent-based perspective